Gentian Diagnostics ASA

Oslo Stock Exchange GENT.OL

Gentian Diagnostics ASA Return on Capital Employed (ROCE) for the year ending December 31, 2023: -6.10%

Gentian Diagnostics ASA Return on Capital Employed (ROCE) is -6.10% for the year ending December 31, 2023, a 54.67% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Gentian Diagnostics ASA Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -13.45%, a -9.05% change year over year.
Gentian Diagnostics ASA Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -12.33%, a -55.04% change year over year.
Gentian Diagnostics ASA Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -7.96%, a 38.41% change year over year.
Gentian Diagnostics ASA Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -12.92%, a -61.91% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Oslo Stock Exchange: GENT.OL

Gentian Diagnostics ASA

CEO	Mr. Njaal Kind
IPO Date	Dec. 14, 2016
Location	Norway
Headquarters	Bjørnåsveien 5
Employees	58
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Medical Instruments Pharmaceuticals

Description

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.

Key trends

Past 5 years